The record
| Class | growth hormone secretagogue |
|---|---|
| Also known as | Egrifta, TH9507, GRF analog |
| Chain length | - |
| Molecular weight | 5,135.9 Da |
| Half-life | 8-11 minutes |
| Route | SC (abdomen) |
| Studied for | HIV-associated lipodystrophy (FDA approved); Visceral adiposity reduction; Cognitive support (investigational) |
| Research use | Body composition studies; Metabolic research; GH axis modulation |
| What has been shown | Significant reduction in trunk fat; Decreased visceral adipose tissue; Improved triglycerides; Increased IGF-1 levels |
| How it works | Stabilized synthetic analog of human GHRH (44 amino acids) with hexenoyl modification at N-terminus for improved stability. Binds to GHRH receptors on pituitary somatotrophs to stimulate GH synthesis and pulsatile release. Subsequently increases IGF-1 and IGFBP-3 levels. Promotes lipolysis and reduces visceral adipose tissue. |
| Patent status | patented |
| Regulatory status | approved |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Fat Loss Signaling Environment (affection, 33%)
- GH Pulsatility Environment (affection, 53%)
- Cognitive support (illness, 100%)
- Fat loss without muscle loss (illness, 30%)
- HIV-associated lipodystrophy (illness, 100%)
- Obesity/weight loss (illness, 30%)
- Prostate cancer (illness, 30%)
- Visceral adiposity reduction (illness, 100%)
- Muscle loss or weakness (symptom, 33%)